← Leaderboards
Boris Decourt
Banner Health
$2,811,849
Attributed
$6,247,689
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2015–23$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,247,689 · 3
By mechanism
R01$5,713,874 · 2
K01$533,815 · 1
Top collaborators
- Marwan Noel Sabbagh9 shared
- Jeffrey R Wilson5 shared
Most similar at Banner Health
Same institution · by research overlap
- Keith A. Johnson$82,231,807
- Reisa A. Sperling$149,869,513
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposCognitionFda ApprovedPharmaceutical PreparationsLenalidomideThalidomideNeuropathologyNeuroinflammationClinical TrialsImpaired CognitionDesignInflammatoryDoseTau ProteinsS DiseaseAmyloid Beta-ProteinBrainInflammationAnalogClinical ResearchAdverse EventTnf GeneAnti-Inflammatory AgentsInflammatory Marker
Grant awards (15)
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients$701,731
R01 · FY2023 · AG
Repurposing Siponimod for Alzheimer's Disease$687,290
R01 · FY2023 · AG
Repurposing Siponimod for Alzheimer's Disease$688,670
R01 · FY2022 · AG
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients$663,871
R01 · FY2022 · AG
Repurposing Siponimod for Alzheimer's Disease$731,856
R01 · FY2021 · AG
Assessment of lenalidomide to treat Alzheimer's disease$639,729
R01 · FY2021 · AG
Administrative Supplement for 1R01AG059008-01: Requested for investigational drug expenses$402,379
R01 · FY2020 · AG
Assessment of lenalidomide to treat Alzheimer's disease$702,328
R01 · FY2019 · AG
Pre-clinical testing of lenalidomide as pleiotropic therapeutics of Alzheimer's disease$101,264
K01 · FY2019 · AG · contact PI
Pre-clinical testing of lenalidomide as pleiotropic therapeutics of Alzheimer's disease$5,499
K01 · FY2019 · AG · contact PI
Assessment of lenalidomide to treat Alzheimer's disease$496,020
R01 · FY2018 · AG
Pre-clinical testing of lenalidomide as pleiotropic therapeutics of Alzheimer's disease$106,763
K01 · FY2018 · AG · contact PI
Pre-clinical testing of lenalidomide as pleiotropic therapeutics of Alzheimer's disease$106,763
K01 · FY2017 · AG · contact PI
Pre-clinical testing of lenalidomide as pleiotropic therapeutics of Alzheimer's disease$106,763
K01 · FY2016 · AG · contact PI
Pre-clinical testing of lenalidomide as pleiotropic therapeutics of Alzheimer's disease$106,763
K01 · FY2015 · AG · contact PI